Future Financial Wealth Managment LLC Has $53,000 Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Future Financial Wealth Managment LLC lifted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 26.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 677 shares of the company’s stock after acquiring an additional 140 shares during the period. Future Financial Wealth Managment LLC’s holdings in GE HealthCare Technologies were worth $53,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of GEHC. Quent Capital LLC lifted its position in shares of GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company’s stock valued at $72,000 after acquiring an additional 119 shares during the period. Greenleaf Trust boosted its position in shares of GE HealthCare Technologies by 1.7% during the 3rd quarter. Greenleaf Trust now owns 7,619 shares of the company’s stock worth $715,000 after purchasing an additional 124 shares in the last quarter. Westside Investment Management Inc. grew its stake in shares of GE HealthCare Technologies by 32.0% in the 3rd quarter. Westside Investment Management Inc. now owns 516 shares of the company’s stock valued at $48,000 after buying an additional 125 shares during the period. EverSource Wealth Advisors LLC increased its position in GE HealthCare Technologies by 8.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company’s stock valued at $135,000 after buying an additional 127 shares in the last quarter. Finally, Quarry LP boosted its holdings in GE HealthCare Technologies by 28.3% in the second quarter. Quarry LP now owns 594 shares of the company’s stock worth $46,000 after acquiring an additional 131 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GEHC. BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Wednesday, September 18th. Evercore ISI upped their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus lifted their target price on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, September 30th. UBS Group downgraded shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $84.00 to $74.00 in a research note on Thursday, September 26th. Finally, Wells Fargo & Company increased their price target on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GE HealthCare Technologies has an average rating of “Moderate Buy” and a consensus target price of $96.00.

GE HealthCare Technologies Stock Performance

Shares of GEHC traded up $0.51 during mid-day trading on Monday, hitting $85.27. 1,269,811 shares of the company traded hands, compared to its average volume of 3,135,044. GE HealthCare Technologies Inc. has a 1 year low of $71.31 and a 1 year high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The stock has a 50-day moving average price of $82.25 and a two-hundred day moving average price of $84.18. The stock has a market cap of $38.96 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 2.90 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to analysts’ expectations of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. GE HealthCare Technologies’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.99 earnings per share. Equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be given a $0.035 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This is an increase from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.85%.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.